In the pharmaceutical industry today, testing the color and haze of a liquid medication is one of the final steps in the manufacturing process. However, in the rush to minimize the number of steps it takes to get a product to market or keep costs down overall, it can be tempting to forego haze testing as a standard part of quality control protocols. After all, analyzing haze has historically required spectrophotometric testing separate from color analysis, which ultimately means an additional investment of valuable time and money. And considering the unprecedented resources that pharmaceutical companies are already spending on research and development efforts, adding another step to the quality control process may seem unnecessarily inefficient.
But haze plays a critical role in shaping consumer perception of liquid pharmaceutical products and eliminating haze testing can compromise product appeal, patient adherence, and patient safety. As such, it is not only wise to measure haze, it may even be critical. And today, it’s easier than ever before, thanks to state-of-the-art technology that ensures you can easily and economically incorporate haze measurement as a standard part of the quality control process.
Cost Efficiency Concerns for Pharmaceutical Companies
The pharmaceutical drug pipeline is longer than ever before. It can take years to go from the initial drug discovery process in the lab to the day the patient finally picks up the medication at their local pharmacy. And for pharmaceutical companies, every one of the hours in between counts. In 2015, pharmaceutical companies spent a total of $141 billion on R&D—up from $108 billion in 2006—and that number is only projected to rise in the future, with experts estimating a total global investment level of $161 billion by 2020.1 Spending on R&D is essential for staying competitive in today’s crowded market, so pharmaceutical companies are constantly looking for other ways to cut costs. From research to development to manufacturing, every test requires both time and manpower, which ultimately means greater investment in the final product.
In today’s pharmaceutical industry, the pressure to cut costs is especially high given the growing public concern about high pharmaceutical drug costs. 2 Pharmaceutical companies confront the dual challenge of making their products affordable for patients while also recouping costs and justifying costs to investors or shareholders. This leaves no room for inefficiency at any point in the research, development, or manufacturing process. Even small efficiency improvements—like using a single spectrophotometer to measure both color and haze or eliminating the need for separate measurement steps—can ultimately have significant financial implications in a world where cost efficiency rules supreme.